SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Merck and Pfizer are to take on the crowded SGLT2 ... day at list price. The US approval has achieved, the companies await similar clearance in Europe, the other leading market for the drugs.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Statistical methods, including a shared frailty model, were employed to evaluate the association between these medications ...

Ideally, you take blood pressure medication so that it’s most effective when your blood pressure is highest. Here’s how to ...

No effect on cardiovascular death There was discussion at ESC whether Kerendia should be used in place of the SGLT2 inhibitors, or in combination, given that all the benefits of the drug were tied ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.